Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023
Descrição
VIENNA, Austria, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry. “It is an incredible honor to be recognized as one of the Fierce 15 biotech companies for 2023,” said Bernd Boidol, Ph.D., chief executive offi
Fierce Biotech on LinkedIn: BrainStorm's ALS cell therapy
Mitchell Pease on LinkedIn: #innovation #biotech #lifesciences
见时知几：2023年Fierce15药企预示着哪些投资趋势- 知乎
Mark Federici on LinkedIn: Crossbow Therapeutics Launches with $80
Fierce Life Sciences Events on LinkedIn: The Future of Biotech
Introducing Fierce Biotech's 2023 Fierce 15
Chris Jenkins on LinkedIn: Introducing Fierce Biotech's 2023 Fierce 15
Mark Federici on LinkedIn: Fierce Biotech Names Proxygen a “Fierce
Jacob Perrett on LinkedIn: What does July's biotech funding reveal
Jacob Perrett on LinkedIn: What does July's biotech funding reveal
Proxygen LinkedIn
Bernd Boidol, Autor bei Proxygen
de
por adulto (o preço varia de acordo com o tamanho do grupo)
